Neuropace Stock Price Prediction
NPCE Stock | USD 13.98 0.02 0.14% |
Oversold Vs Overbought
54
Oversold | Overbought |
Neuropace stock price prediction is an act of determining the future value of Neuropace shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Neuropace's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Neuropace and does not consider all of the tangible or intangible factors available from Neuropace's fundamental data. We analyze noise-free headlines and recent hype associated with Neuropace, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Neuropace's stock price prediction:EPS Estimate Next Quarter (0.34) | EPS Estimate Current Year (1.16) | EPS Estimate Next Year (1.02) | Wall Street Target Price 17.83 | EPS Estimate Current Quarter (0.31) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Neuropace based on different types of headlines from major news networks to social media. The Neuropace stock price prediction module provides an analysis of price elasticity to changes in media outlook on Neuropace over a specific investment horizon. Using Neuropace hype-based prediction, you can estimate the value of Neuropace from the perspective of Neuropace response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Neuropace. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Neuropace to buy its stock at a price that has no basis in reality. In that case, they are not buying Neuropace because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Neuropace after-hype prediction price | USD 14.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Neuropace |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuropace's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuropace After-Hype Price Prediction Density Analysis
As far as predicting the price of Neuropace at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Neuropace or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Neuropace, with the unreliable approximations that try to describe financial returns.
Next price density |
Expected price to next headline |
Neuropace Estimiated After-Hype Price Volatility
In the context of predicting Neuropace's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Neuropace's historical news coverage. Neuropace's after-hype downside and upside margins for the prediction period are 9.60 and 18.40, respectively. We have considered Neuropace's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Neuropace is slightly risky at this time. Analysis and calculation of next after-hype price of Neuropace is based on 3 months time horizon.
Neuropace Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Neuropace is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuropace backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Neuropace, there might be something going there, and it might present an excellent short sale opportunity.
Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 4.40 | 0.00 | 0.00 | 9 Events / Month | 5 Events / Month | In about 9 days |
Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
13.98 | 14.00 | 0.00 |
|
Neuropace Hype Timeline
Neuropace is now traded for 13.98. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Neuropace is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at 0.0%. %. The volatility of related hype on Neuropace is about 164.95%, with the expected price after the next announcement by competition of 13.98. About 79.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.27. Neuropace had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 9 days. Check out Neuropace Basic Forecasting Models to cross-verify your projections.Neuropace Related Hype Analysis
Having access to credible news sources related to Neuropace's direct competition is more important than ever and may enhance your ability to predict Neuropace's future price movements. Getting to know how Neuropace's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Neuropace may potentially react to the hype associated with one of its peers.
HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
A | Agilent Technologies | 1.40 | 9 per month | 1.44 | (0.02) | 2.26 | (2.44) | 6.31 | |
ILMN | Illumina | 2.01 | 10 per month | 0.00 | (0.12) | 3.65 | (3.83) | 9.89 | |
WAT | Waters | 1.35 | 11 per month | 0.00 | (0.07) | 2.55 | (3.04) | 7.95 | |
TMO | Thermo Fisher Scientific | (4.99) | 8 per month | 1.28 | (0.05) | 1.80 | (1.63) | 6.87 | |
MTD | Mettler Toledo International | (18.65) | 7 per month | 1.82 | (0.03) | 2.48 | (3.26) | 6.80 | |
CRL | Charles River Laboratories | (2.39) | 9 per month | 1.57 | 0.05 | 2.87 | (2.57) | 15.05 | |
GH | Guardant Health | (0.35) | 11 per month | 0.00 | (0.13) | 5.82 | (7.29) | 22.73 | |
RVTY | Revvity | 0.28 | 12 per month | 0.00 | (0.11) | 2.09 | (3.33) | 8.67 |
Neuropace Additional Predictive Modules
Most predictive techniques to examine Neuropace price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Neuropace using various technical indicators. When you analyze Neuropace charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
About Neuropace Predictive Indicators
The successful prediction of Neuropace stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Neuropace, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Neuropace based on analysis of Neuropace hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Neuropace's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Neuropace's related companies. 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 8.53 | 6.07 | 7.42 | 9.92 | Days Of Inventory On Hand | 243.02 | 272.12 | 236.61 | 276.82 |
Story Coverage note for Neuropace
The number of cover stories for Neuropace depends on current market conditions and Neuropace's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Neuropace is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Neuropace's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Neuropace Short Properties
Neuropace's future price predictability will typically decrease when Neuropace's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Neuropace often depends not only on the future outlook of the potential Neuropace's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neuropace's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 25.9 M | |
Cash And Short Term Investments | 66.5 M |
Check out Neuropace Basic Forecasting Models to cross-verify your projections. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.Note that the Neuropace information on this page should be used as a complementary analysis to other Neuropace's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Neuropace's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 2.531 | Quarterly Revenue Growth 0.408 | Return On Assets (0.15) | Return On Equity (1.19) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.